Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | PTPRA | P18433 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.37 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2431567 | 0.82 | P2RX7 (0.36) | LMNAALDH1A1SMN1; SMN2HTTGAA | |
| SCHEMBL22610222 | 0.81 | MAPK1 (0.41) | ALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL895915 | 0.78 | SMN1; SMN2 (0.41) | LMNAALDH1A1SMN1; SMN2HTTGAA | |
| SCHEMBL2680153 | 0.77 | ALDH1A1 (0.55) | LMNAALDH1A1SMN1; SMN2HTTGAA | |
| SCHEMBL17825462 | 0.75 | P4HTM (0.54) | SMN1; SMN2PTPRACYP1A2PTGS1HSD17B10 | |
| SCHEMBL6178335 | 0.74 | P2RX7 (0.42) | LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL895866 | 0.73 | KCNQ2 (0.42) | LMNAALDH1A1SMN1; SMN2HTTAKR1C3 | |
| SCHEMBL895816 | 0.73 | AKR1C3 (0.41) | LMNAALDH1A1SMN1; SMN2HTTGAA | |
| SCHEMBL4061265 | 0.72 | ALDH1A1 (0.43) | LMNAALDH1A1SMN1; SMN2HTTGAA | |
| SCHEMBL8831554 | 0.71 | PTGS2 (0.42) | LMNAALDH1A1SMN1; SMN2PTPRACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0654035-B1 | PHOSPHONOACETIC ESTERS AND ACIDS AS ANTI-INFLAMMATORIES | UPJOHN CO (US) | 1997-08-20 | — | — | EP | claimed |
| US-5565441-A | AN N-HETEROCYCLE DERIVATIVE; ANTIARTHRITIC AGENTS; DISEASES CHARACTERIZED BY ABNORMAL PHOSPHATE AND CALCIUM METABOLISM; CHRONIC DISEASES | THE UPJOHN COMPANY (US) | 1996-10-15 | — | — | US | claimed |
| EP-0654035-A1 | PHOSPHONOACETIC ESTERS AND ACIDS AS ANTI-INFLAMMATORIES. | UPJOHN CO (US) | 1995-05-24 | — | — | EP | claimed |
| WO-1994003463-A1 | PHOSPHONOACETIC ESTERS AND ACIDS AS ANTI-INFLAMMATORIES | THE UPJOHN COMPANY (US) | 1994-02-17 | — | — | WO | claimed |
| US-20120083605-A1 | PYRIDAZINE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED | 2012-04-05 | — | — | US | disclosed |
| EP-0654035-B1 | PHOSPHONOACETIC ESTERS AND ACIDS AS ANTI-INFLAMMATORIES | UPJOHN CO (US) | 1997-08-20 | — | — | EP | disclosed |
| US-5643895-A | Phosphonoacetic esters and acids as anti-inflammatories | THE UPJOHN COMPANY (US) | 1997-07-01 | — | — | US | disclosed |
| US-5565441-A | AN N-HETEROCYCLE DERIVATIVE; ANTIARTHRITIC AGENTS; DISEASES CHARACTERIZED BY ABNORMAL PHOSPHATE AND CALCIUM METABOLISM; CHRONIC DISEASES | THE UPJOHN COMPANY (US) | 1996-10-15 | — | — | US | disclosed |
| EP-0654035-A1 | PHOSPHONOACETIC ESTERS AND ACIDS AS ANTI-INFLAMMATORIES. | UPJOHN CO (US) | 1995-05-24 | — | — | EP | disclosed |
| WO-1994003463-A1 | PHOSPHONOACETIC ESTERS AND ACIDS AS ANTI-INFLAMMATORIES | THE UPJOHN COMPANY (US) | 1994-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083605-A1 | PYRIDAZINE COMPOUND AND USE THEREOF | PLPBP, PNPO, PDXK | LMNA 2869/4885ALDH1A1 3397/4885SMN1; SMN2 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.